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Abstract We analysed population-based treatment and
survival data of patients who presented with metastatic rectal
cancer. All patients diagnosed with primary synchronous
metastatic rectal cancer between 1992 and 2008 in the Eind-
hoven Cancer Registry area were included. Date of diagnosis
was divided into three periods (1992–1999, 2000–2004,
2005–2008) according to the availability of chemotherapy
type. We assessed treatment patterns and overall survival
according to period of diagnosis. The proportion of
patients diagnosed with stage IV disease increased from
16% in 1992–1999 to 20% in 2005–2008 (P\0.0001).
Chemotherapyuseincreasedfrom5%in1992to61%in2008
(P\0.0001). Resection rates of the primary tumour
decreased from 65% in 1992 to 27% in 2008 (P\0.0001),
while metastasectomy rates remained constant since 1999
(9%). Median survival increased from 38 weeks (95% con-
ﬁdence interval (CI) 32–44) in 1992–1999 to 53 weeks (95%
CI 48–61) in 2005–2008. Among patients not receiving che-
motherapy median survival remained approximately
30 weeks. Multivariable analysis conﬁrmed the lower risk of
death among patients diagnosed in more recent years.
Increased use of chemotherapy went together with improved
median survival among patients with metastatic rectal cancer
in the last two decades. Stage migration as an effect of more
effectiveimagingproceduresislikelytobepartlyresponsible
for this improved survival.
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Abbreviations
ECR Eindhoven cancer registry
TNM Tumour node classiﬁcation
ICD-O International classiﬁcation of disease-oncology
SES Socioeconomic status
5-FU 5-Fluoruracil
HR Hazard ratio
CL Conﬁdence limits
Introduction
Colorectal cancer is one of the leading causes of cancer
worldwide. It is the third most common type of cancer in
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DOI 10.1007/s10585-010-9370-8men in the Netherlands (14%) and the second most com-
mon type of cancer in women (13%). In 2008 in the
Netherlands, 12,127 new cases of colorectal cancer were
diagnosed [1]. Of these, 3,986 were rectal cancers. Primary
treatment for resectable rectal carcinoma is surgical
resection in combination with preoperative radiotherapy
[2]. One ﬁfth of patients with rectal cancer in the Nether-
lands present with metastatic disease [3], and treatment is
palliative for patients with non-resectable metastases [4].
For years, 5-ﬂuorouracil (5-FU) based chemotherapy
remained the cornerstone of chemotherapy in colorectal
cancer. Since 2000, with the introduction of the new agents
oxaliplatin and irinotecan and from 2005 with combination
of chemotherapy with targeted therapy drugs, such as
bevacizumab and cetuximab response rate and overall
survival data further improved [5–11].
Recently, we published population-based survival data
of patients who presented with metastatic colon cancer at
diagnosis in the period from 1990 to 2004 [12]. Remark-
ably, the survival of patients who did not receive palliative
chemotherapy remained only 22 weeks. Survival of
patients receiving chemotherapy increased, however, from
54 weeks in the period 1990–1994 to 72 weeks in
2003–2004. Patients who presented with metastatic rectal
cancer might differ from colon cancer with respect to
(presenting) symptoms, treatment and biological behaviour
[13]. In this study we report the results of the population-
based survival data of the patients who presented with
metastatic rectal cancer in the period from 1992 until 2008
in the south of the Netherlands.
Methods
Population-based data from the Eindhoven Cancer Registry
(ECR) was used, which is maintained by the Comprehen-
sive Cancer Centre South. The ECR records data on all
patients newly diagnosed with cancer in the southern part of
the Netherlands, an area with 2.3 million inhabitants. The
ECR is served by 10 community hospitals, six pathology
departments, and two radiotherapy institutes. Data on
patient characteristics like gender, date of birth, and postal
code and tumour characteristics like date of diagnosis,
tumour type, histology, subsite, stage, and treatment are
routinely extracted from the medical records by trained
registrars. The quality of the data is consistent due to
thorough training of the registration clerks and computer-
ised consistency checks at regional and national level. The
completeness of the registration is estimated to exceed 95%.
All patients diagnosed with primary metastatic cancer
of the rectum or rectosigmoid junction (anatomical
tumour location C19–C20, according to the International
Classiﬁcation of Diseases for Oncology ICD-O-3 [14])
from 1992 to 2008 in the registration area of the ECR were
included (n = 1,319). Patients with cancer diagnosed at
autopsy were excluded. Stage of the disease was deﬁned
according to tumour–lymph node–metastasis (TNM) clas-
siﬁcation [15]. Data on localisation of metastases were
available on organ level, also in case of multiple locations
in different organs. No information was available on the
number of metastatic lesions within an organ, nor on the
size of the metastatic lesions. Chemotherapy (yes versus
no) was deﬁned as prescription of any chemotherapy at
initial diagnosis and up to 6 months after. Date of diagnosis
was divided into three periods according to the availability
of chemotherapy for metastatic rectal cancer patients:
1992–1999 (period in which a relatively small part of
patients with metastatic rectal cancer received chemother-
apy), 2000–2004 (main treatment remained 5-FU based
therapy), and 2005–2008 (combination therapy more gen-
erally used, also due to the CAIRO study [16], including
increased use of targeted therapy drugs). Radiotherapy was
deﬁned as radiotherapy directed at the primary tumour, or
directed at metastases, where appropriate. Surgery was
deﬁned as resection of the primary tumour, or as metas-
tasectomy (resection of metastases in any organ), where
appropriate.
Prognostically relevant concomitant conditions are
recorded from the medical records according to a slightly
adapted version of the Charlson Index, on a routine basis
since 1995 [17, 18]. Socio-economic status (SES) of the
patient was deﬁned at neighborhood level (based on postal
code of residence area, 17 households on average) com-
bining mean household income and mean value of the
house/apartment [19]. The latter was derived from indi-
vidual ﬁscal data made available at an aggregated level.
Postal codes were assigned to one of 3 SES categories: low
(1st–3rd decile), intermediate (4th–7th decile), and high
(8th–10th decile). For patients residing in nursing homes, a
special SES category was assigned.
Differences in the receipt of chemotherapy between
periods of diagnosis and between patient and tumour fac-
tors were tested for by means of a v
2 test. A multivariable
logistic regression analysis was performed in order to
identify the independent inﬂuence of the aforementioned
factors.
Follow-up of vital status of all patients was complete up
to 1 January 2010. In addition to passive follow-up via the
hospitals, this information was actively obtained from the
municipal personal records database. Crude survival rates
were computed according to patient and tumour charac-
teristics. Survival time was deﬁned as the time from
diagnosis to death or 1 January 2010 for the patients
who were still alive. A log-rank test was carried out to
evaluate signiﬁcant differences between survival curves.
A multivariable proportional hazards regression analysis
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123was used to discriminate independent risk factors for death.
To investigate the effect of treatment on any improvement
in survival over time, a model including and a model
excluding the various treatment options was built. SAS/
STAT statistical software (SAS system 9.1, SAS Institute,
Cary, NC) was used for the analyses.
Results
The proportion of patients with rectal cancer diagnosed
with synchronous metastases (stage IV) increased from
16% in 1992–1999 to 20% in 2005–2008 (P\0.0001)
(Table 1).
Overall, the proportion of patients treated with chemo-
therapy increased from 27% in 1992–1999 to 58% in
2005–2008 (P\0.0001) (Table 2). Both among younger
and older patients administration of chemotherapy
increased, although large age-related differences remained.
Patients with a high socio-economic status (SES) and those
without comorbidity more frequently received chemother-
apy, as did male patients in the most recent period.
Chemotherapy rates by year of diagnosis are depicted in
Fig. 1a, showing the apparent increase over time (61% in
2008) (P\0.0001). As can be seen in the same ﬁgure,
resection rates of the primary tumour decreased from 65%
in 1992 to 27% in 2008 (P[0.0001). Metastasectomy
rates increased until 1999 up to 9%, and remained rela-
tively stable afterwards (P = 0.3). In Fig. 1b, trends in
referral for radiotherapy are depicted. Radiotherapy rates
directed at the primary tumour, not preceded or followed
by a resection, also remained relatively constant over time,
while pre- or postoperative radiotherapy rates increased up
to 2002, and declined after 2004, coupled to the lower
resection rates in these years (P\0.0001).
Crude overall survival rates improved between the ﬁrst
two periods, and remained stable in 2005–2008 (Fig. 2).
Median survival increased from 38 weeks (CL 32–44) in
1992–1999 to 50 weeks in 2000–2005 (CL 45–59), and to
53 weeks (CL 48–61) in 2005–2008 (Table 3). Median
Table 1 Proportion of patients with rectal cancer diagnosed with
synchronous metastases (stage IV), as a proportion of stage I–IV
patients diagnosed with rectal cancer between 1992 and 2008 in the
south of the Netherlands, by period of diagnosis
Period of diagnosis Proportion M1 at diagnosis (%)
1992–1999 16
2000–2004 19
2005–2008 20
a
a v
2 test of difference in stage distribution between periods of diag-
nosis, P-value\0.0001
Table 2 General characteristics
including proportion of patients
receiving chemotherapy (CT)
a Registered since 1993;
patients diagnosed in 1992
designated to ‘unknown
comorbidity’
b v
2 test of difference in
chemotherapy use between
periods of diagnosis
* P-value[0.05 (v
2 test of
difference in chemotherapy use
between values of one variable
within the same period of
diagnosis, excluding unknown
category)
** P-value[0.01 (v
2 test of
difference in chemotherapy use
between values of one variable
within the same period of
diagnosis, excluding unknown
category)
1992–1999 2000–2004 2005–2008
n CT (%) n CT (%) n CT (%)
Overall 415 27 456 47 448 58**
b
Age
\70 243 37 283 61 251 76
70? 172 12** 173 24** 197 36**
Gender
Male 261 29 281 47 281 62
Female 154 24 175 46 167 52*
Socio-economic status
Low 92 21 125 39 126 56
Intermediate 169 31 190 50 1778 58
High 116 30 115 56 123 64
Institutionalised 22 9 17 18** 11 0**
Unknown 16 25 9 22 11 73
Comorbidity
a
None 174 34 168 54 150 69
One comorbid condition 116 25 135 47 127 58
Two or more comorbid conditions 62 19 98 34** 135 47**
Unknown 63 19 55 49 36 53
Site of metastasis
Liver only 255 29 261 50 237 58
Other 160 24 195 43 211 58
Clin Exp Metastasis (2011) 28:283–290 285
123survival of patients receiving chemotherapy also showed
an increasing trend until 2000–2004 without any further
improvement afterwards, although conﬁdence limits over-
lapped throughout the whole study period. For patients
with metastases conﬁned to the liver, an improving trend
could be noted from 41 weeks in 1992–1999 to 67 weeks
in 2000–2004. Afterwards, median survival remained
constant for these patients. Median survival of patients who
were not treated with chemotherapy remained dismal over
time, at around 30 weeks. In Table 4, median survival is
depicted according to patient characteristics.
The improvement in median survival seen in Table 3
seems to be largely caused by improved survival among
patients aged 70 or younger (from 46 to 73 weeks). Median
survival remained constant among older patients.
Remarkably, the increase in median survival was larger
among males compared to females, especially in the most
recent period (median survival 2005–2008: males 62
(53–72) weeks; females 42 (29–51) weeks.
In Table 5, the results of a multivariable proportional
hazards regression analysis are shown. After adjustment for
all variables listed including not only various modes of
treatment but also SES and anatomic sublocalisation, a
lower risk of death could be observed for patients diag-
nosed in more recent years. Furthermore, of prognostic
value were age, presence of comorbidity, depth of pene-
tration, nodal status, localisation of metastases, chemo-
therapy use, metastasectomy, and radiotherapy directed at
the primary tumour. Undergoing a resection of the primary
tumour was of borderline statistical signiﬁcance. Although
after inclusion of treatment variables (model 2) the effect
of period of diagnosis decreased somewhat compared to
the model without adjustment for treatment (model 1), a
signiﬁcant effect of period of diagnosis remained, which
means that other factors besides treatment were likely to be
partly responsible for the decreased risk of death observed
in more recent years, such as stage migration.
Discussion
In this population-based study we investigated the survival
of patients presenting with metastatic rectal cancer in the
south of the Netherlands between 1992 and 2008. The
proportion of patients presenting with stage IV rectal
cancer in the Eindhoven Cancer Registry increased from
16% in the period 1992–1999 to 20% in the period
2005–2008. The most probable explanation of this phe-
nomenon is stage migration. In the last decennium the
diagnostic work-up for rectal cancer has changed dramat-
ically, with standard use of procedures like MRI and/or
endo-echography of the rectum and CT scan of thorax
and abdomen to exclude metastasis. Stage migration is
important to consider when interpreting any stage speciﬁc
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Fig. 1 Trend in treatment of patients with rectal cancer and
synchronous metastases in the south of the Netherlands, 1992–2006.
a Chemotherapy and resection (black line Chemotherapy, grey line
Resection of primary tumour, dashed grey line Metastasectomy).
b Radiotherapy (black line Radiotherapy without resection (primary
tumour), grey line pre- or postoperative radiotherapy (primary
tumour), dashed grey line radiotherapy (metastases))
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Fig. 2 Crude survival (in weeks) of patients with rectal cancer and
synchronous metastases in the south of the Netherlands, by period of
diagnosis. dashed grey line 1992–1999, grey line 2000–2004, black
line 2005–2008
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123improvements in cancer [20]. Of interest is that in our
study, the overall survival in patients not receiving che-
motherapy remained stable over time at about 30 weeks,
which is longer in comparison to other published series in
metastatic colorectal cancer, including our data on stage IV
colon cancer showing survival of 22 weeks [12]. This
survival beneﬁt in stage IV rectal cancer might be caused
by a more early diagnosis of rectal cancer due to more
alarming symptoms (e.g. rectal bleeding, tenesmus,
incomplete defecation) and thus lower tumor load at time
of diagnosis resulting in a prolonged survival. Another
explanation could be the fact that rectal cancer has a dif-
ferent biological behavior. Different genetic abnormali-
ties have been found in colorectal cancers from different
sites. Proximal colon cancer is usually related to the
nucleotide instability pathway, as microsatellite instability
(MSI) and distal cancer are associated with special chro-
mosomal instability (CIN). These differences might be
partially explained by different embryological develop-
ment and physiological circumstances. [13, 21, 22] Also
environmental factors such as diet and alcohol inﬂuence
the development of tumors at different sites of the colo-
rectum [22]. The possible different biological behavior of
rectal cancer might partly explain the lower effectiveness
of adjuvant chemotherapy in non-metastatic rectal cancer.
Our study showed that the median overall survival of
metastatic rectal cancer patients increased signiﬁcantly
from 38 weeks in the period 1992–1999 to 53 weeks in the
period 2005–2008. Among patients receiving chemother-
apy the median survival was about 75 weeks. The use of
palliative chemotherapy kept increasing until 2006, and
remained constant afterwards at 60–65%. For patients older
than 70 years there was a threefold increase from 12% to
36% between 1992–1999 and 2005–2008. It can be spec-
ulated that this remarkable increase in the use of chemo-
therapy among older patients suggests that these patients
are increasingly reasonably ﬁt with limited tumor related
symptoms. However, there may also be an increased
awareness of the beneﬁts of palliative chemotherapy by the
oncologist, patient and family.
For patients receiving chemotherapy since 2000 the
median overall survival remained constant, despite the use
of more and newer cytostatic drugs and biological therapies
in recent years. This might partly be caused by the rather
limited number of patients (despite the population-based
nature of our study), but might also indicate that at popu-
lation level, patients with metastatic rectal cancer do not
beneﬁt from the availability of oxaliplatin and targeted
therapies in addition to 5-FU-based treatment. It is possible
that a relatively large proportion of the patients did not
receive combination chemotherapy, but unfortunately, we
only had data available on whether a patient received
chemotherapy, not on the type or combinations of che-
motherapy. Among patients with metastases conﬁned to the
liver, median overall survival also seemed to level off after
2000. A possible explanation for the improved survival of
patients with metastases conﬁned to the liver compared to
the 1990 s may be an improved outcome after liver
resection [23, 24], and an increased proportion of patients
becoming eligible for curative liver resection after
Table 3 Median survival (in
weeks) of patients with rectal
cancer and synchronous
metastases, according to receipt
of chemotherapy, and separately
for patients with metastases
conﬁned to the liver, by period
of diagnosis
CL conﬁdence limits
Median survival in weeks (CL)
All patients Patients
receiving
chemotherapy
Patients with
metastases
conﬁned to liver
Patients not
receiving
chemotherapy
1992–1999 38 (32–44) 67 (56–76) 41 (32–51) 29 (24–35)
2000–2004 50 (45–59) 79 (65–91) 67 (57–80) 33 (27–39)
2005–2008 53 (48–61) 75 (66–89) 64 (53–75) 25 (19–31)
Table 4 Median survival (in weeks) of patients with rectal cancer and synchronous metastases, according to patient characteristics, by period of
diagnosis
Median survival in weeks (CL)
Age Gender Socio-economic status Comorbidity
\70 70? Male Female Low Inter-
mediate
High None One
comorbid
condition
CTwo
comorbid
conditions
1992–1999 46 (39–57) 28 (21–35) 36 (28–45) 39 (32–48) 38 (29–45) 41 (29–51) 40 (27–57) 45 (36–35) 33 (25–51) 33 (19–40)
2000–2004 65 (53–78) 34 (28–40) 50 (40–64) 51 (43–64) 47 (35–57) 52 (40–65) 63 (45–81) 63 (49–77) 49 (39–65) 36 (26–49)
2005–2008 73 (59–89) 34 (27–42) 62 (53–72) 42 (29–51) 51 (37–61) 56 (47–69) 60 (48–71) 71 (49–91) 53 (36–66) 49 (37–58)
CL conﬁdence limits
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123neoadjuvant chemotherapy [25–27]. The fact that survival
tended to decrease over time among patients who did not
receive chemotherapy can be explained by the large
increase in chemotherapy administration rates, leaving
behind the patients who are most frail, or have the most
widespread disease. Younger patients (\70 years)
accounted almost fully for the observed increases in sur-
vival of the total group. Interestingly, males showed a
much larger improvement in most recent years compared to
females. This may be partly explained by a lower chemo-
therapy administration rate among females; we are not
aware of gender-related differences in effectiveness of
modern chemotherapy regimens.
After adjustment for patient- and tumour factors, a more
recent period of diagnosis was associated with a lower
hazard ratio (risk of death). After additional adjustment for
Table 5 Multivariable
proportional hazards regression
analyses for patients diagnosed
with synchronous metastatic
rectal cancer in the south of the
Netherlands, 1992–2008
a Adjusted for all listed
variables including socio-
economic status and anatomic
sublocalisation (rectosigmoid
junction vs. rectum)
b Reference category
Model 1, not adjusted for
treatment
a
Model 2, adjusted for
treatment
a
HR P-value HR P-value
Period of diagnosis
1992–1999 1.8 \0.0001 1.5 \0.0001
2000–2004 1.3 0.0005 1.3 0.003
2005–2008
b 1.0 1.0
Age (years)
\70
b 1.0 1.0
70? 1.4 \0.0001 1.2 0.009
Gender
Males
b 1.0 1.0
Females 1.0 0.5 1.1 0.3
Comorbidity
No comorbidity
b 1.0 1.0
One comorbid condition 1.0 0.7 1.1 0.6
Two or more comorbid conditions 1.2 0.03 1.2 0.09
Depth of penetration, primary tumour
T1,2 0.6 0.004 0.6 0.004
T3
b 1.0 1.0
T4 1.2 0.01 1.4 0.0006
Nodal status
N0 0.7 0.0002 0.7 0.0002
N1,2
b 1.0 1.0
Localisation of metastases
Liver only
b 1.0 1.0
Other 0.9 0.006 0.9 0.02
Chemotherapy use
No
b 1.0
Yes 0.5 \0.0001
Metastasectomy
No
b 1.0
Yes 0.5 \0.0001
Resection of primary tumour
No
b 1.0
Yes 0.3 0.07
Radiotherapy directed at primary tumour
No
b 1.0
Yes 0.7 \0.0001
Radiotherapy directed at metastases
No
b 1.0
Yes 1.2 0.2
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123relevant treatment modalities such as chemotherapy, a
more recent period of diagnosis was still associated with a
lower hazard ratio. This means that chemotherapy was not
fully responsible for the improvements in survival. This
means that other factors such as stage migration played an
important part, which is not unexpected in view of the
growing proportion of patients being diagnosed with met-
astatic disease. This means that an increasing proportion of
patients is probably diagnosed with smaller and/or fewer
metastatic lesions due to increasingly more effective
imaging techniques. These patients, who tended to be
wrongfully diagnosed as M0 patients in the past, have a
better prognosis solely based on the less widespread extent
of disease. Unfortunately, no on the size and number of
metastatic lesions without lesions information was avail-
able in our study. Also the hazard ratios of speciﬁc treat-
ment modalities have to be interpreted with caution, in
view of the retrospective nature of this study; it is likely
that selection of ﬁtter patients for a certain treatment
(‘confounding by indication’) has biased the results. For
example, chemotherapy was associated with a hazard ratio
of 0.5, but this ﬁgure is biased in the context of a retro-
spective, non-randomised study as ours.
Our data show that with the increased use of chemother-
apy and probably stage migration there was a decrease in
local treatment with surgery, radiotherapy, or the combina-
tion of both therapies. Some authors have pled in favour of
primary systemic chemotherapy in the treatment of meta-
staticrectalcancerandsuggestthatsurgeryandradiotherapy
should be reserved for patients presenting with resectable
metastatic disease or severe symptoms of bowel obstruction
[28–30]. From our retrospective data, it is not possible to
draw conclusions on any beneﬁcial or harmful effect of the
decreased resection rates of the primary tumour.
In conclusion, the results of this population-based study
among patients with metastatic rectal cancer showed a
relatively long median survival of patients without sys-
temic treatment. The administration of chemotherapy
increased from 5% in 1992 to 61% in 2008, together with a
reduction in the use of surgery and radiotherapy, while
median survival improved from 38 to 53 weeks.
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